CLLS Stock Discussion
Cellectis S.A. Description
Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company's products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Solid Tumors Acute Myeloid Leukemia Leukemia Blastoma Multiple Myeloma Glioblastoma Hematologic Malignancies Oncogenes Genome Chimeric Antigen Receptor Chronic Lymphocytic Leukemia Lymphocytic Leukemia Adoptive Cell Transfer Tumors Of The Hematopoietic And Lymphoid Tissues CD19 Cell Product Acute Lymphoblastic Leukemia Cellectis
Recent Comments
- Cos3 on Adding float as advanced filter criteria?
- FriendlyOyster657 on BOOT
- TraderMike on Filtering by News?
- Dr_Duru on Filtering by News?
- TraderMike on Filtering by News?
From the Blog
Popular Now
Featured Articles